HYLORIS overview

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 million Stronger growth expected in 2024 of both sales and gross margin, mainly fueled by the recent launch in the U.S. of Maxigesic® IV and Podofilox gel, the global roll out of Maxigesic IV® and commercial deals Increased operating R&D expenses while net operating cash outflow remained stable versus 2022 Significant R&D progress including clinical and regulatory...

Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) , a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET. Following the release, the company will host a live webcast to discuss 2023 results and the outlook for 2024. Participants will...

Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients in the EU and U.S. will be randomized to receive either tranexamic acid oral solution or placebo Last patient out expected around end of 2024 Study results expected first half of 2025 Liège, Belgium – February, 14 2024 – 6PM CET – Non-regulated information - Hyloris Pharmaceuticals SA...

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 29 1 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information –...